Blocking endogenous IL-6 impairs mobilization of free fatty acids during rest and exercise in lean and obese men.
Level 3 - non-randomized controlled study
Non-randomized, placebo-controlled crossover clinical trial
PubMed 34622233 · doi:10.1016/j.xcrm.2021.100396
What was done
In a placebo-controlled, non-randomized, participant-blinded crossover study, researchers administered the IL-6 receptor antagonist tocilizumab or placebo to lean and obese men. They evaluated systemic energy metabolism, free fatty acid appearance, lipolysis (glycerol appearance rate), fatty acid oxidation, and glucose kinetics during rest, exercise, and recovery using tracer dilution methodology.
What was found
The abstract reports directional findings without numerical values or statistical estimates. Tocilizumab reduced circulating fatty acid appearance across rest, exercise, and recovery in both lean and obese participants. Lipolysis (rate of glycerol appearance), fatty acid oxidation, and glucose kinetics were not meaningfully altered, indicating that reduced fatty acid availability was driven by increased fatty acid re-esterification rather than suppressed triglyceride breakdown.
Why it matters
This study identifies a physiological role for endogenous IL-6 in regulating fatty acid mobilization in humans, offering a potential metabolic mechanism for the adipose tissue expansion and weight gain reported with therapeutic IL-6 inhibition.
Limits
The trial was non-randomized, restricted to male participants, and the abstract omits sample size, participant baseline characteristics, and exact quantitative data with confidence intervals. Long-term metabolic and body composition changes were not assessed.
Cited by
- supports Administering an inflammatory marker without physical tissue damage can induce physiological adaptive responses.